Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
RESEARCH TOOLSreports
Phathom Pharmaceuticals (PHAT) Stock Price & Analysis
211 Followers
PHAT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $17.02
Previous Close$9.48
Volume421.17K
Average Volume (3M)906.78K
Market Cap
$554.37M
Enterprise Value$312.00M
Total Cash (Recent Filing)$381.39M
Total Debt (Recent Filing)$139.03M
Price to Earnings (P/E)-2.4
Beta1.49
Next Earnings
May 07, 2024EPS Estimate
-$1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding58,477,351
10 Day Avg. Volume951,079
30 Day Avg. Volume906,777
Standard Deviation0.21
R-Squared0.03
Alpha-0.00164
Financial Highlights & Ratios
Price to Book (P/B)-8.06
Price to Sales (P/S)840.29
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue457.48
Enterprise Value/Gross Profit605.83
Enterprise Value/Ebitda-1.99
Forecast
1Y Price Target
$21.33Price Target Upside125.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Phathom Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market AcceptanceV oquezna had its strongest week yet and has had significant TRx add the last two weeks, showing growing market acceptance.
Product LaunchV oquezna was launched in the U.S. for Erosive GERD and H. pylori infection, indicating a new treatment option in the market.
Revenue Performance2023 product revenue exceeded Visible Alpha Consensus and Goldman Sachs estimates, demonstrating strong financial performance.
Bears Say
Data AccuracyIQVIA does not capture all Voquezna TRx, meaning some prescription data is not accounted for in the analysis.
Drug UptakeThere were a few softer weeks in late March for Voquezna, implying potential volatility or challenges in its uptake.
Financial EstimatesAnalysts have lowered the 1Q24 sales estimate for Voquezna to $1.7M, which also brings down the full year 2024 estimate.
---
Ownership Overview
40.17% Insiders
7.45% Mutual Funds
20.26% Other Institutional Investors
32.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $6.07 and its highest was $17.02 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Currently, no data Available
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is May 07, 2024 which is in 18 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Mar 07, 2024. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.077 by -$0.313.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -$1.23.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 58,477,352 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.077. Following the earnings report the stock price went down -6.578%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Among the largest hedge funds holding Phathom Pharmaceuticals’s share is Gilder Gagnon Howe & Co LLC.. It holds Phathom Pharmaceuticals’s shares valued at 13M.
---
Phathom Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.33 (125.00% Upside)
$21.33 (125.00% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 541.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
151.10%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
---
PHAT Earnings Call
Q4 2024
0:00 / 0:00
---
PHAT Stock 12 Months Forecast
Average Price Target
$21.33
▲(125.00% Upside)
Technical Analysis
Best Analysts Covering PHAT
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+4.93%
assigned a buy rating 4 months ago
Copying Sean Kim PhD's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +4.93% per trade.
---